カレントテラピー　36-10　サンプル page 25/30

このページは カレントテラピー　36-10　サンプル の電子ブックに掲載されている25ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　36-10　サンプル

94 Current Therapy 2018 Vol.36 No.101020想される．骨代謝の基礎研究では新たなメカニズムやシーズ探索が続けられるであろうが，骨粗鬆症の臨床研究ではこれらの治療薬の適切な使い分け，切り替え，休薬などが当面の検討課題となるであろう．参考文献1）van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE：Sclerostin deficiency in humans. Bone 96：51-62, 20172）Van Buchem FS, Hadders HN, Ubbens R：An uncommonfamilial systemic disease of the skeleton：hyperostosis corticalisgeneralisata familiaris. Acta radiol 44：109-120, 19553）Balemans W, Patel N, Ebeling M, et al：Identification of a 52kb deletion downstream of the SOST gene in patients withvan Buchem disease. J Med Genet 39：91-97, 20024）Gong Y, Slee RB, Fukai N, et al；Osteoporosis-PseudogliomaSyndrome Collaborative Group：LDL receptor-related protein5（LRP5）affects bone accrual and eye development.Cell 107：513-523, 20015）Boyden LM, Mao J, Belsky J, et al：High bone density due toa mutation in LDL-receptor-related protein 5. N Engl J Med346：1513-1521, 20026）Winkler DG, Sutherland MK, Geoghegan JC, et al：Osteocytecontrol of bone formation via sclerostin, a novel BMP antagonist.EMBO J 22：6267-6276, 20037）Semenov M, Tamai K, He X：SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280：26770-26775, 20058）Leupin O, Piters E, Halleux C, et al：Bone overgrowth-associatedmutations in the LRP4 gene impair sclerostin facilitatorfunction. J Biol Chem 286：19489-19500, 20119）Kusu N, Laurikkala J, Imanishi M, et al：Sclerostin is a novelsecreted osteoclast -derived bone morphogenetic proteinantagonist with unique ligand specificity. J Biol Chem 278：24113-24117, 200310）Padhi D, Jang G, Stouch B, et al：Single-dose, placebo-controlled,randomized study of AMG 785, a sclerostin monoclonalantibody. J Bone Miner Res 26：19-26, 201111）McClung MR1, Grauer A, Boonen S, et al：Romosozumab inpostmenopausal women with low bone mineral density. NEngl J Med 370：412-420, 201412）Langdahl BL, Libanati C, Crittenden DB, et al：Romosozumab（sclerostin monoclonal antibody）versus teriparatide in postmenopausalwomen with osteoporosis transitioning from oralbisphosphonate therapy：a randomised, open-label, phase 3trial. Lancet 390：1585-1594, 201713）Cosman F, Crittenden DB, Adachi JD, et al：RomosozumabTreatment in Postmenopausal Women with Osteoporosis. NEngl J Med 375：1532-1543, 201614）Cosman F, Crittenden DB, Ferrari S, et al：RomosozumabFRAME Study：A Post Hoc Analysis of the Role of RegionalBackground Fracture Risk on Nonvertebral FractureOutcome. J Bone Miner Res 33：1407-1416, 201815）McClung MR, Brown JP, Diez-Perez A, et al：Effects of 24Months of Treatment With Romosozumab Followed by 12Months of Denosumab or Placebo in Postmenopausal WomenWith Low Bone Mineral Density：A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 33：1397-1406, 201816）Alzahrani MM, Rauch F, Hamdy RC：Does SclerostinDepletion Stimulate Fracture Healing in a Mouse Model?Clin Orthop Relat Res 474：1294-1302, 201617）Feng G, Chang-Qing Z, Yi-Min C, et al：Systemic administrationof sclerostin monoclonal antibody accelerates fracturehealing in the femoral osteotomy model of young rats. IntImmunopharmacol 24：7-13, 201518）Miller PD, Hattersley G, Riis BJ, et al；ACTIVE StudyInvestigators：Effect of Abaloparatide vs Placebo on NewVertebral Fractures in Postmenopausal Women WithOsteoporosis：A Randomized Clinical Trial. JAMA 316：722-733, 201619）Varela A, Chouinard L, Lesage E, et al：One year of abaloparatide,a selective peptide activator of the PTH1 receptor,increased bone mass and strength in ovariectomized rats.Bone 95：143-150, 201720）Tsuchie H, Miyakoshi N, Kasukawa Y, et al：The effect ofteriparatide to alleviate pain and to prevent vertebral collapseafter fresh osteoporotic vertebral fracture. J BoneMiner Metab 34：86-91, 2016